Patients suffering from severe asthma and EGPA frequently show a super-response to anti-IL-5/IL-5R biologics, despite showing worse baseline clinical features, such as more severe exacerbations and more frequent use of systemic corticosteroidshttps://bit.ly/45DCRZi. This evidence concerns the gene IL5 and asthma.